March 2 - 5, 2020
Hard Rock Hotel
San Diego, California
Abstract submission deadline: Tuesday, December 3
Advance registration deadline: Friday, January 17
Conference CochairsCory Abate-Shen, Columbia University Irving Comprehensive Cancer Center, New York, New YorkAndrea Califano, Columbia University Medical School, New York, New YorkJos Jonkers, Netherlands Cancer Institute, Amsterdam, NetherlandsCalvin J. Kuo, Stanford University, Stanford, California
A veritable explosion of cancer models in recent years has been fueled by technological advances that have enabled the rapid generation of models of increasing complexity and relevance for human cancer. Genetically engineered mouse (GEM) models and cancer cell lines are mainstays for basic and translational cancer research; organoids and patient-derived xenograft (PDX) models are allowing for a better recapitulation of cancer characteristics; and cell-based computational modeling simulates single-cell behavior in virtual tissues of cancer systems. These next-generation models have, in turn, provided key insights into all aspects of cancer biology, including elucidating the actions of stem cells and developmental pathways and the impact of lineage plasticity, understanding metastatic progression, uncovering the roles of the tumor microenvironment and immune system, exploring tumor evolution, and discovering new therapeutic approaches and mechanisms of drug sensitivity and adaptive response. This meeting will highlight recent advances in modeling cancer using mouse models, cell lines, organoids, PDX models, and computational models, focusing on their impact for advancing our understanding of cancer biology, prevention and treatment, and drug response and resistance.
For information on tabletop exhibits please contact email@example.com. Space is limited.